Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SK-BR-3 Volasertib
0.00031623
PLK
Cell cycle
 1.0373 0.00381
SK-BR-3 Doxorubicin
0.00031623
Chemo
Chemotherapy
 0.9595 -0.00239
MDA-MB-361 Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9582 0.00538
MDA-MB-157 INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.9745 -0.00090
MDA-MB-157 Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 1.0129 0.00004
MDA-MB-157 Neratinib
0.00031623
EGFR/HER2
RTK
 1.0337 0.00251
MCF7 Volasertib
0.00031623
PLK
Cell cycle
 1.0510 0.00013
MDA-MB-361 Palbociclib
0.00031623
CDK4/6
Cell cycle
 0.9651 0.00223
MDA-MB-157 Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9547 0.00231
MCF7 Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 0.9150 0.00711
SK-BR-3 Palbociclib
0.00031623
CDK4/6
Cell cycle
 1.0488 -0.00133
MDA-MB-157 Luminespib
0.00031623
HSP90
Misc
 1.0143 0.00005
MDA-MB-436 Luminespib
0.00031623
HSP90
Misc
 0.9733 -0.00344
CAL-51 Trametinib
0.00031623
MEK
MAPK/nRTK
 1.0233 0.00194
MDA-MB-157 Volasertib
0.00031623
PLK
Cell cycle
 1.0814 -0.00135
MCF7 Palbociclib
0.00031623
CDK4/6
Cell cycle
 1.0497 -0.00053
MDA-MB-157 Palbociclib
0.00031623
CDK4/6
Cell cycle
 0.9482 0.00160
MDA-MB-157 Dinaciclib
0.00031623
pan CDK
Cell cycle
 1.0629 -0.00194
MDA-MB-231 INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.9572 0.00181
MDA-MB-134-VI Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 1.0531 0.00467
MDA-MB-134-VI INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.9671 -0.00323
MDA-MB-134-VI Luminespib
0.00031623
HSP90
Misc
 1.3361 -0.01039
MDA-MB-231 Neratinib
0.00031623
EGFR/HER2
RTK
 0.9892 0.00060
MDA-MB-134-VI Neratinib
0.00031623
EGFR/HER2
RTK
 1.3354 0.00352
MDA-MB-157 Doxorubicin
0.00031623
Chemo
Chemotherapy
 0.9388 0.00482